Medical and Pharmaceutical
A recent review suggests natural settings and activities can complement all stages of psychedelic-assisted therapy
Hi, what are you looking for?
Mugglehead Investment Magazine
Psychedelics
Analysis
With solid efficacy and low cost, the popular club drug could help curb the personal toll and multi-billion dollar cost of North America's battle...
Canada
Proposed by Health Canada, the change would allow patients to access restricted substances like MDMA through the Special Access Program
Psychedelics
With major research, legal reform, and more than 20 firms going public, it was major year for the re-emerging field
Analysis
Following a surge of interest, ibogaine therapy in the country disappeared. But recent signs show regulators are warming to the promising plant
Health and Safety
After a successful ballot measure, a broad set of onlookers focuses on Oregon to gauge the social and economic impacts of licensed psilocybin therapy
Investment Ideas
Through its university partnership, the firm wants to attract big pharma backers by making 100,000s of novel psychedelic derivatives for new precision medicine
Psychedelics
A first-of-its-kind clinical trial shows a dramatic drop in depression in over half of patients who received a synthetic version of the compound
International
In September, the Michigan city halted enforcement related to all entheogenic plants. Officials hope the move will inspire other moderate jurisdictions
Cannabis
Many of the firm's well-known faces took lumps in the weed sector, mistakes they say set them up for success in psychedelics
